Investment group

Cairn Investment Group Inc. strengthens its position in Pfizer Inc. (NYSE: PFE)


Cairn Investment Group Inc. increased its holdings in Pfizer Inc. (NYSE: PFE – Get Rating) by 4.0% during the 1st quarter, according to its latest communication with the SEC. The company held 22,821 shares of the biopharmaceutical company after purchasing an additional 870 shares during the period. Cairn Investment Group Inc.’s holdings in Pfizer were worth $1,783,000 at the end of the most recent period.

A number of other hedge funds and other institutional investors also bought and sold shares of PFE. Central Bank & Trust Co. increased its stake in Pfizer shares by 17.0% during the fourth quarter. Central Bank & Trust Co. now owns 24,163 shares of the biopharmaceutical company valued at $1,427,000 after purchasing 3,518 additional shares during the period. The First Midwest Bank Trust division increased its stake in Pfizer shares by 5.6% during the fourth quarter. The First Midwest Bank Trust division now owns 89,409 shares of the biopharmaceutical company valued at $5,279,000 after purchasing an additional 4,775 shares during the period. HNP Capital LLC increased its stake in Pfizer shares by 12.0% during the fourth quarter. HNP Capital LLC now owns 18,221 shares of the biopharmaceutical company valued at $1,076,000 after purchasing an additional 1,948 shares during the period. Global Trust Asset Management LLC increased its stake in Pfizer shares by 4.9% during the fourth quarter. Global Trust Asset Management LLC now owns 58,988 shares of the biopharmaceutical company valued at $3,483,000 after purchasing an additional 2,776 shares during the period. Finally, Crescent Capital Consulting LLC increased its stake in Pfizer shares by 11.9% during the fourth quarter. Crescent Capital Consulting LLC now owns 71,672 shares of the biopharmaceutical company valued at $4,235,000 after purchasing an additional 7,627 shares during the period. Hedge funds and other institutional investors own 66.50% of the company’s shares.

Shares of PFE opened at $53.17 on Monday. Pfizer Inc. has a 1-year low of $39.46 and a 1-year high of $61.71. The company has a market cap of $298.33 billion, a price-to-earnings ratio of 12.19, a growth price-to-earnings ratio of 0.64, and a beta of 0.73. The company has a debt ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39. The company has a fifty-day moving average of $50.98 and a 200-day moving average of $51.79.

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly results on Tuesday, May 3. The biopharmaceutical company reported earnings per share (EPS) of $1.62 for the quarter, missing the consensus estimate of $1.66 per ($0.04). Pfizer had a net margin of 26.97% and a return on equity of 38.29%. The company posted revenue of $25.66 billion for the quarter, versus analyst estimates of $24.73 billion. During the same period last year, the company posted EPS of $0.93. The company’s revenues increased by 76.8% compared to the same quarter last year. Analysts predict that Pfizer Inc. will post EPS of 6.63 for the current year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Wednesday, June 29 will receive a dividend of $0.40 per share. This represents an annualized dividend of $1.60 and a dividend yield of 3.01%. The ex-date of this dividend is Thursday, July 28. Pfizer’s dividend payout ratio (DPR) is 36.70%.

In a similar vein, SVP Jennifer B. Damico sold 4,218 Pfizer shares in a trade dated Tuesday, June 7. The shares were sold at an average price of $53.96, for a total transaction of $227,603.28. Following the sale, the senior vice president now directly owns 10,846 shares of the company, valued at $585,250.16. The sale was disclosed in a filing with the SEC, which is available on the SEC’s website. Additionally, Executive Vice President William R. Carapezzi, Jr. sold 32,908 Pfizer shares in a trade dated Thursday, May 12. The shares were sold at an average price of $50.00, for a total transaction of $1,645,400.00. Following the sale, the executive vice president now owns 38,146 shares of the company, valued at $1,907,300. The disclosure of this sale can be found here. In the past three months, insiders have sold 41,126 shares of the company valued at $2,075,003. Company insiders hold 0.05% of the company’s shares.

A number of analysts have recently released reports on PFE shares. StockNews.com upgraded Pfizer shares from a “buy” rating to a “strong buy” rating in a Tuesday, April 19 research note. SVB Leerink launched coverage on Pfizer shares in a research report on Monday, May 23. They set a “market performance” rating and a price target of $55.00 for the company. Wells Fargo & Company cut its price target on Pfizer shares from $60.00 to $55.00 in a Wednesday, May 4, research report. Berenberg Bank set a price target of $50.00 on Pfizer shares in a research report on Friday, May 27. Finally, JPMorgan Chase & Co. set a price target of $57.00 on Pfizer shares in a Tuesday, June 28 research report. Nine equity research analysts gave the stock a hold rating, ten issued a buy rating and one gave the company’s stock a high buy rating. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $56.95.

Pfizer Company Profile (Get an assessment)

Pfizer Inc discovers, develops, manufactures, markets, distributes and sells biopharmaceuticals worldwide. It offers drugs and vaccines in various therapeutic areas, including cardiovascular, metabolic and women’s health under the Premarin Family and Eliquis brands; biologics, small molecules, immunotherapies and biosimilars under the brands Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena and Braftovi; and sterile injectable and anti-infective drugs, and oral COVID-19 treatment under the brands Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga and Paxlovid.

Featured articles

Institutional ownership by quarter for Pfizer (NYSE:PFE)



Get news and reviews for Pfizer Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.